BCL6 and breast carcinoma: Additionally, the availability of a small molecule inhibitor that targets resistance screen hit BCL6 (BCL6i, 79‐6) [32], and the lack of prior studies assessing the effect of BCL6 on drug response, prompted us to investigate the role of BCL6 in paclitaxel response in breast cancer.